Page 3

3.1 Overview 35 3.2 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Global 35 3.3 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Global 37 3.4 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - The US 38 3.5 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - The US 39 3.6 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - France 40 3.7 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - France 41 3.8 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Germany 42 3.9 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Germany 43 3.10 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Italy 44 3.11 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Italy 45 3.12 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Spain 46 3.13 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Spain 47 3.14 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - The UK 48 3.15 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - The UK 49 3.16 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Japan 50 3.17 PTSD Therapeutics Market Forecast (2011-2019) - Japan 51 3.18 Drivers and Barriers for the Posttraumatic Stress Disorder Therapeutics Market 52 3.18.1 Drivers for the Posttraumatic Stress Disorder Therapeutics Market 52 3.18.2 Barriers for the Posttraumatic Stress Disorder Therapeutics Market 52 3.19 Opportunity and Unmet Need Analysis 53 3.20 Key Takeaway 54 4 Posttraumatic Stress Disorder Therapeutics - Competitive Assessment 55 4.1 Overview 55 4.2 Strategic Competitor Assessment 55 4.3 Product Profiles for the Major Marketed Products in the Posttraumatic Stress Disorder Therapeutics Market 56 4.3.1 Selective Serotonin Reuptake Inhibitors (SSRIs) 56 4.3.2 Paxil (paroxetine) 57 4.3.3 Zoloft (sertraline) 58 4.3.4 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) 59 4.3.5 Atypical Antipsychotics 60 4.4 Key Takeaway 60 5 Posttraumatic Stress Disorder Therapeutics - Pipeline Assessment 61 5.1 Overview 61 5.2 Strategic Pipeline Assessment 61 5.3 Posttraumatic Stress Disorder Therapeutics Pipeline - Pipeline by Phases of Development 62 5.3.1 Posttraumatic Stress Disorder Therapeutics - Phase III Pipeline 62 5.3.2 Posttraumatic Stress Disorder Therapeutics - Phase II Pipeline 63 5.3.3 Posttraumatic Stress Disorder Therapeutics - Phase I Pipeline 63 5.3.4 Posttraumatic Stress Disorder Therapeutics - Pre-clinical Pipeline 63 5.3.5 Posttraumatic Stress Disorder Therapeutics - Discovery Pipeline 64 5.3.6 Technology Trends Analytic Framework 64 5.4 Posttraumatic Stress Disorder Therapeutics Market -Pipeline by Mechanism of Action 66 5.5 Molecule Profile for Promising Drugs under Clinical Development 67 5.5.1 Avlocardyl (propranolol) 67 5.6 Key Takeaway 67 6 Posttraumatic Stress Disorder Therapeutics - Clinical Trials Mapping 68 6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 68

Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019  

the industry analysis specialist, has released its new report, “Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and...